Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cerecor Inc (CERC)

Cerecor Inc (CERC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

CERC : 2.93 (-1.68%)
AVTX : 7.00 (-22.65%)
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...

CERC : 2.93 (-1.68%)
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies,...

CERC : 2.93 (-1.68%)
HRZN : 11.05 (+0.36%)
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

ROCKVILLE, Md. and CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...

CERC : 2.93 (-1.68%)
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets

Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders

CERC : 2.93 (-1.68%)
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance

ROCKVILLE, Md. and CHESTERBROOK, Pa., June 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...

CERC : 2.93 (-1.68%)
HRZN : 11.05 (+0.36%)
Cerecor to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of...

CERC : 2.93 (-1.68%)
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of...

CERC : 2.93 (-1.68%)
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments...

CERC : 2.93 (-1.68%)
Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments...

CERC : 2.93 (-1.68%)

Barchart Exclusives

3 AI Stocks to Buy Instead of Super Micro Computer
Following a significant drop in Super Micro Computer's stock due to a delayed 10-K filing and accounting concerns, investors are exploring alternative AI infrastructure stocks like Dell, Arista Networks, and Pure Storage, which offer strong growth prospects in the rapidly expanding AI market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar